| Literature DB >> 30791871 |
Beatrice Huang1, Denise De Vore2, Chris Chirinos2, Jessica Wolf2, Devon Low2, Rachel Willard-Grace2, Stephanie Tsao3, Chris Garvey4, Doranne Donesky5, George Su6, David H Thom7.
Abstract
BACKGROUND: Recruitment and retention are two significant barriers in research, particularly for historically underrepresented groups, including racial and ethnic minorities, patients who are low-income, or people with substance use or mental health issues. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and disproportionately affects many underrepresented groups. The lack of representation of these groups in research limits the generalizability and applicability of clinical research and results. In this paper we describe our experience and rates of recruitment and retention of underrepresented groups for the Aides in Respiration (AIR) COPD Health Coaching Study.Entities:
Keywords: Chronic obstructive pulmonary disease; Patient selection; Research design; Vulnerable populations
Mesh:
Year: 2019 PMID: 30791871 PMCID: PMC6385381 DOI: 10.1186/s12874-019-0679-y
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Study design characteristics to support enrollment and retention of underrepresented minorities
| Area of focus | Design Characteristic |
|---|---|
| Community interaction | Conducting study in safety net community clinics [ |
| Working with community-based patient partners [ | |
| Partnering with community clinics [ | |
| Meeting with patients and stakeholders over course of study (study advisory board) [ | |
| Clinic interaction | Creating value for clinical care (e.g., providing test results to primary care clinicians) [ |
| Providing education to clinic staff [ | |
| Payments to clinics [ | |
| Basing study activities at community clinics [ | |
| Patient interaction | Providing information to patient about their condition [ |
| Bilingual staff and study materials [ | |
| Training research staff in outreach, recruitment and retention, especially for minority and underserved populations [ | |
| Recruitment | Face to face recruitment and enrollment when possible [ |
| Minimal inclusion/exclusion criteria [ | |
| Not requiring patient to endorse diagnosis of condition [ | |
| Retention | Meeting with patient at home or close to where patient lived [ |
| Continuity of personal relationship with member of study team [ | |
| Maintaining contact at 3 month intervals [ | |
| Both recruitment and retention | Flexibility in rescheduling meeting times [ |
| Providing compensation to patients [ |
Challenges faced during the study and solutions
| Challenges | Solution |
|---|---|
| Lack of spirometric data by which to identify eligible patients | Worked in conjunction with the spirometry community program |
| Limited patient access due to poor health and transportation barriers | Flexibility in scheduling, accepting no shows and rescheduling, meeting patients closer to home, meeting with patients during their medical visits, home visits |
| Space constraints at clinic | Scheduling around times where space is available, using more than one visit if space not available for sufficient time, meeting patients outside of the clinic setting |
| Diverted attention | Prioritization of recruitment |
| Loss to follow up (by phone) | Other forms of communications used (letters, emergency contacts) |
| Poor patient health | Home visits |
Characteristics, from review of health record, of patients enrolled compared to all eligible patients
| Enrolled | Eligible, not enrolled | ||
|---|---|---|---|
| Age, in years, mean (sd) | 61.6 (7.6) | 65.9 (9.1) | |
| Male, % (n/N) | 68% (125/192) | 71% (63/90) | |
| Primary language other than English, % (n/N) | 10.7% (18/169) | 8.1% (7/86) | |
| > 1 hospitalization in 12 months prior to recruitment, % (n/N) | 30.2% (58/192) | 31.1% (28/90) | |
| Uses oxygen at home, % (n/N) | 6.3% (12/190) | 12.2% (11/90) | |
| Prescription for LAMA or LABA+ICS*, % (n/N) | 78.7% (151/192) | 84.4% (76/90) |
* LAMA Long-acting muscarinic agent; LABA Long-acting beta-antagonist; ICS Inhaled corticosteroid
Characteristics of patients retained compared to all patients enrolled
| Enrolled | Completed study | Did not complete study ( | P-value* | |
|---|---|---|---|---|
| At enrollment | ||||
| Age, in years, mean (sd) | 61.3 (7.6) | 61.3 (7.5) | 61.1 (8.5) | |
| Male, % (n/N) | 65.5 (126/192) | 63.9% (101/158) | 73.5% (25/34) | |
| Preferred Language | ||||
| English, % (n/N) | 87.4% (167/191) | 86.6% (136/157) | 91.2% (31/34) | |
| Spanish, % (n/N) | 9.4% (18/191) | 10.2% (16/157) | 5.9% (2/34) | |
| Other, % (n/N) | 3.1% (6/191) | 3.2% (5/157) | 2.9% (1/34) | |
| Race | ||||
| African-American, % (n/N) | 56.7% (109/192) | 55.7% (88/158) | 61.8% (21/34) | p = .52 |
| White, % (n/N) | 21.3% (41/192) | 20.9% (33/158) | 23.5% (8/34) | |
| Asian, % (n/N) | 3.6% (7/192) | 4.4% (7/158) | 0.0% (0/34) | |
| Other, % (n/N) | 16.1% (31/192) | 19.0% (30/158) | 14.7% (5/34) | |
| Ethnicity- Latino/Hispanic, % (n/N) | 16.7% (32/192) | 17.7% (28/158) | 11.8% (4/34) | |
| Substance use, % (n/N) | 28.6% (55/192) | 26.6% (42/158) | 38.2% (13/34) | |
| PHQ score ≥ 15, % (n/N) | 15.7% (30/192) | 16.6% (26/158) | 11.8% (4/34) | |
| < High school education, % (n/N) | 31.9% (61/191) | 31.9% (50/157) | 32.4% (11/34) | |
| Limited health literacy**, % (n/N) | 37.2% (71/191) | 39.5% (62/157) | 26.5% (9/34) | |
| FEV1 < 50% predicted | 38.8% (59/152) | 38.0% (49/129) | 43.5% (10/23) | |
| Gold category D, % (n/N) | 46.3% (88/190) | 45.2% (71/157) | 51.5% (17/33) | |
| During study period | ||||
| > 1 hospitalization, % (n/N) | 25.0% (48/192) | 22.2% (35/158) | 38.2% (13/34) | |
| > 1 hospitalization for COPD, % (n/N) | 18.2% (35/192) | 17.7% (28/158) | 20.6% (7/34) | |
| Uses oxygen at home, % (n/N) | 18.3% (35/191) | 14.7% (23/157) | 35.3% (12/34) | |
*For completed study vs did not complete study
**Needs someone to help read medial information at least a little of the time